Skip Navigation

European Journal of Heart Failure 2006 8(6):571-576; doi:10.1016/j.ejheart.2005.11.016
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Herrmann, M.
Right arrow Articles by Herrmann, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrmann, M.
Right arrow Articles by Herrmann, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society of Cardiology

A review of homocysteine and heart failure

Markus Herrmanna,*, Omid Taban-Shomala, Ulrich Hübnera, Michael Böhmb and Wolfgang Herrmanna

a Institut für Klinische Chemie und Laboratoriumsmedizin/Zentrallabor, Universitätsklinikum des Saarlandes D-66421 Homburg/Saar, Germany
b Klinik für Innere Medizin III, Universitätsklinikum des Saarland D-66421 Homburg/Saar, Germany

* Corresponding author. Tel.: +49 6841 1630707; fax: +49 6841 1630703. E-mail address: markusherr{at}aol.com


   Abstract

Chronic heart failure (CHF) is a major public health problem causing considerable morbidity and mortality. Recently, plasma homocysteine (HCY) has been suggested to be increased in CHF patients potentially representing a newly recognized risk marker. This manuscript reviews the existing literature regarding hyperhomocysteinemia (HHCY) and CHF. Clinical data indicate that HHCY is associated with an increased incidence of CHF as well as with the severity of the disease. Mechanistic studies of HHCY and CHF are rare. However, preliminary results suggest that HHCY causes adverse cardiac remodelling characterized by interstitial and perivascular fibrosis resulting in increased myocardial stiffness. In addition, HHCY seems to affect the pump function of the myocardium. The mechanisms leading from an elevated HCY level to reduced pump function and adverse cardiac remodelling are a matter of speculation. Existing data indicate that direct effects of HCY on the myocardium as well as NO independent vascular effects are involved. In conclusion, HHCY might be a potential aetiological factor in CHF. Future studies need to clarify the mechanistic role of HHCY in CHF as a useful paradigm with most interesting therapeutic implications, because HCY lowering therapy could favourably influence the prognosis in CHF patients.

Key Words: Homocysteine • Heart failure • Remodelling • Pump function • Incidence • Severity of disease

Received June 8, 2005; Revised September 23, 2005; Accepted November 29, 2005


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Annals of Clinical & Laboratory ScienceHome page
S. Badiou, S. Bariolet, A.-M. Dupuy, A. Sultan, A. Avignon, and J.-P. Cristol
A New DiaSys Colorimetric Assay for Plasma Homocysteine: Application in Diabetic Patients
Ann. Clin. Lab. Sci., January 1, 2009; 39(3): 233 - 240.
[Abstract] [Full Text] [PDF]


Home page
jvdiHome page
S. Rossi, G. Rossi, A. Giordano, and S. Paltrinieri
Homocysteine measurement by an enzymatic method and potential role of homocysteine as a biomarker in dogs
J Vet Diagn Invest, September 1, 2008; 20(5): 644 - 649.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.